Isolated pelvic perfusion: Plasma pharmacokinetics depend primarily on drug dosage and not the type of drug

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 4, 2005, Pages 318-322

  Belliveau, James F ^a   Arevalo, Elisabeth ^a   Griffin, Hank ^a   Wanebo, Harold J ^b  

^a PROVIDENCE COLLEGE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical pharmacology; Pelvic perfusion; Pharmacokinetics

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; OXALIPLATIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; FOOD AND DRUG ADMINISTRATION; HUMAN; MODEL; PELVIS; PELVIS CANCER; PLASMA CLEARANCE; PREDICTION; PRIORITY JOURNAL;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; ORGANOPLATINUM COMPOUNDS; PELVIC NEOPLASMS;

EID: 15044366138     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0895-x     Document Type: Article

References (10)

1. Belliveau J, Wanebo H (2003) Clinical experiences and pharmacology with isolated pelvic perfusion (IPP) for lower GI cancers. Proceedings of the 14th International Congress on Anti-Cancer Treatment, Paris (P059) 14:206
2. Creech O, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148:616
3. Darnowski JW, Sawyer RC, Stolfi RL, Martin DS, Lau-Cam CA (1985) Decreased host toxicity in vivo during chronic treatment with 5-fluorouracil. Cancer Chemother Pharmacol 14:63
4. Forastiere AA, Belliveau JF, Goren M, Vogel WC, Posner MC, O'Leary GP (1988) Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloro-platinum (II) in head and neck cancer patients. Cancer Res 48:3869
5. den Hartigh J, van Oort WJ (1981) High-pressure liquid chromatographic determination of the antitumor agent mitomycin C in human blood plasma. Anal Chim Acta 127:47
6. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 52:1855
7. Schmoll HJ (2002) The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. Semin Oncol 29 [Suppl 15]:34
8. Turk PS, Belliveau JF, Darnowski JW, Weinberg MC, Leenen L, Wanebo HJ (1993) Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. Arch Surg 128:533
9. Wanebo HJ, Belliveau JF (1999) A pharmacokinetic model and the clinical pharmacology of cisplatin, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion. Cancer Chemother Pharmacol 43:427
10. Wanebo HJ, Chung MD, Levy AI, Turk PS, Vezeridis MP, Belliveau JF (1996) Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon occlusion technique. Ann Surg Oncol 3:295